15-87933033-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_001012338.3(NTRK3):c.1868G>A(p.Gly623Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as other (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G623A) has been classified as Uncertain significance.
Frequency
Consequence
NM_001012338.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NTRK3 | NM_001012338.3 | c.1868G>A | p.Gly623Glu | missense_variant | 16/20 | ENST00000629765.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NTRK3 | ENST00000629765.3 | c.1868G>A | p.Gly623Glu | missense_variant | 16/20 | 1 | NM_001012338.3 |
Frequencies
GnomAD3 genomes ? Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome ? Cov.: 33
ClinVar
Submissions by phenotype
Cabozantinib resistance;na:Entrectinib resistance;na:Larotrectinib resistance;na:Repotrectinib resistance;na:Selitrectinib resistance Other:1
other, no assertion criteria provided | research | Davare Laboratory, Oregon Health & Science University | - | Kinase domain mutation within ETV6-NTRK3 fusion imposes resistance to multiple NTRK kinase inhibitors; Induces drug resistance when present in context of ETV6-NTRK3 fusion protein; Patient tumor harboring this mutation progressed on NTRK targeted therapy. In cell based assays, ETV6-NTRK3 with NTRK3 G623E mutation conferred high level of resistance to multiple NTRK tyrosine kinase inhibitors. Likely unresponsive to NTRK inhibitors |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.